Kenilworth-based Merck has
announced the company is discontinuing development of its COVID-19 vaccine
candidates, V590 and V591.
The decision follows the company’s
review of findings from Phase 1 clinical studies for the vaccines.
In the studies, both V590
and V591 were generally well tolerated, but the immune responses were inferior
to those seen following natural infection and those reported for other
SARS-CoV-2/COVID-19 vaccines.
The company now plans to
focus its COVID-19 research strategy and production capabilities on advancing
two therapeutic candidates, MK-4482 and MK-7110.
For more information, click
here.